Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

Daily Technical Summary Reports on Biotech Stocks -- Juno Therapeutics, Lexicon Pharma, NantKwest, and Nektar Therapeutics

PR Newswire July 7, 2017

Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City

PR Newswire June 6, 2017

Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire June 5, 2017

Watch These 7 Huge Call Purchases In Monday Trade

Benzinga.com  June 5, 2017

Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics

PR Newswire May 25, 2017

New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds

PR Newswire May 22, 2017

Nektar Therapeutics Announces Data Presentations at ASCO 2017

PR Newswire May 18, 2017

Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York

PR Newswire May 15, 2017

Nektar Therapeutics Reports Financial Results for the First Quarter of 2017

PR Newswire May 9, 2017

Investor Network: Nektar Therapeutics to Host Earnings Call

Accesswire May 9, 2017

Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program

PR Newswire May 3, 2017

Nektar to Announce Financial Results for the First Quarter of 2017 on Tuesday, May 9, 2017, After Close of U.S.-Based Financial Markets

PR Newswire May 2, 2017

Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting

PR Newswire April 20, 2017

Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting

PR Newswire April 4, 2017

Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders

PR Newswire March 27, 2017

Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide

Benzinga.com  March 20, 2017

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  March 20, 2017

Mid-Morning Market Update: Markets Mostly Flat; Washington Companies Proposes To Acquire Dominion Diamond

Benzinga.com  March 20, 2017

NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

PR Newswire March 20, 2017

Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics, Dynavax Technologies, and BioMarin Pharma

PR Newswire March 13, 2017